STADA Arzneimittel AG (SAZ) Given Consensus Recommendation of “Sell” by Brokerages

STADA Arzneimittel AG (ETR:SAZ) has been given an average rating of “Sell” by the six analysts that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is €74.08 ($88.18).

SAZ has been the subject of several recent research reports. Nord/LB set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a report on Wednesday, December 20th. Warburg Research set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a report on Wednesday, December 20th. Independent Research set a €89.00 ($105.95) price objective on STADA Arzneimittel and gave the stock a “neutral” rating in a report on Tuesday, December 26th. Commerzbank set a €66.25 ($78.87) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a report on Tuesday, December 26th. Finally, S&P Global set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the stock a “sell” rating in a report on Friday, November 10th.

Shares of STADA Arzneimittel (ETR SAZ) opened at €88.36 ($105.19) on Friday. STADA Arzneimittel has a 1-year low of €46.31 ($55.13) and a 1-year high of €89.76 ($106.86). The stock has a market capitalization of $5,510.00 and a price-to-earnings ratio of 58.13.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/28/stada-arzneimittel-ag-saz-given-consensus-recommendation-of-sell-by-brokerages.html.

STADA Arzneimittel Company Profile

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply